ZY
Zymergen Inc. [ZY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ZY Stock Summary
In the News
ZY Financial details
Company Rating
Neutral
Market Cap
0
Income
-364.95M
Revenue
14.09M
Book val./share
2.29
Cash/share
2.06
Dividend
-
Dividend %
-
Employees
502
Optionable
No
Shortable
Yes
Earnings
03 Nov 2022
P/E
-1.33
Forward P/E
-
PEG
-0.41
P/S
-
P/B
1.06
P/C
-
P/FCF
-
Quick Ratio
4.16
Current Ratio
4.59
Debt / Equity
0.79
LT Debt / Equity
0.75
-
-
EPS (TTM)
-3.55
EPS next Y
-
EPS next Q
-
EPS this Y
81.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-46.93%
EPS Q/Q
61.43%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
58.19%
Inst Trans
1.05%
ROA
-40%
ROE
-65%
ROC
-0.41%
Gross Margin
-218%
Oper. Margin
-2456%
Profit Margin
-2705%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.1-11.87
52W High
-
52W Low
-
RSI
-
Rel Volume
2.26
Avg Volume
1.04M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
ZY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.16 | 0.14 | 0.23 | |
| Net income per share | -2.42 | -2.68 | -4.87 | |
| Operating cash flow per share | -2 | -2.28 | -4.07 | |
| Free cash flow per share | -2.23 | -2.45 | -4.52 | |
| Cash per share | 1.48 | 2.16 | 5.2 | |
| Book value per share | -5.1 | -7.59 | 5.5 | |
| Tangible book value per share | -5.17 | -7.76 | 4.84 | |
| Share holders equity per share | -5.1 | -7.59 | 5.5 | |
| Interest debt per share | 0.83 | 0.92 | 0.79 | |
| Market cap | 3.69B | 3.69B | 497.11M | |
| Enterprise value | 3.62B | 3.56B | 154.95M | |
| P/E ratio | -15.57 | -14.06 | -1.37 | |
| Price to sales ratio | 239.15 | 277.59 | 29.69 | |
| POCF ratio | -18.86 | -16.52 | -1.64 | |
| PFCF ratio | -16.88 | -15.34 | -1.48 | |
| P/B Ratio | -7.38 | -4.96 | 1.22 | |
| PTB ratio | -7.38 | -4.96 | 1.22 | |
| EV to sales | 234.92 | 267.74 | 9.25 | |
| Enterprise value over EBITDA | -16.57 | -15.29 | -0.47 | |
| EV to operating cash flow | -18.52 | -15.93 | -0.51 | |
| EV to free cash flow | -16.58 | -14.8 | -0.46 | |
| Earnings yield | -0.06 | -0.07 | -0.73 | |
| Free cash flow yield | -0.06 | -0.07 | -0.68 | |
| Debt to equity | -0.16 | -0.11 | 0.11 | |
| Debt to assets | 0.34 | 0.26 | 0.08 | |
| Net debt to EBITDA | 0.3 | 0.56 | 1.05 | |
| Current ratio | 1.49 | 1.88 | 5.54 | |
| Interest coverage | -80.57 | -22 | -23.6 | |
| Income quality | 0.83 | 0.85 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.97 | 4.52 | 4.96 | |
| Research and developement to revenue | 3.29 | 6.84 | 9.5 | |
| Intangibles to total assets | 0.03 | 0.05 | 0.09 | |
| Capex to operating cash flow | 0.12 | 0.08 | 0.11 | |
| Capex to revenue | -1.48 | -1.29 | -2 | |
| Capex to depreciation | -1.5 | -0.92 | -1.62 | |
| Stock based compensation to revenue | 0.26 | 0.36 | 1.27 | |
| Graham number | 16.66 | 21.39 | 24.54 | |
| ROIC | 0.56 | 0.36 | -0.77 | |
| Return on tangible assets | -1.07 | -0.91 | -0.76 | |
| Graham Net | -5.91 | -8.49 | 3.73 | |
| Working capital | 54.32M | 107.12M | 333.8M | |
| Tangible asset value | -506.18M | -760.13M | 359.31M | |
| Net current asset value | -561.47M | -820.08M | 293.44M | |
| Invested capital | -0.16 | -0.11 | 0.11 | |
| Average receivables | 0 | 3.83M | 3.85M | |
| Average payables | 0 | 13.17M | 8.76M | |
| Average inventory | 0 | 3.6M | 5.5M | |
| Days sales outstanding | 72.15 | 126.56 | 67.25 | |
| Days payables outstanding | 50.65 | 52.06 | 28.36 | |
| Days of inventory on hand | 7.92 | 21.38 | 31.59 | |
| Receivables turnover | 5.06 | 2.88 | 5.43 | |
| Payables turnover | 7.21 | 7.01 | 12.87 | |
| Inventory turnover | 46.07 | 17.07 | 11.55 | |
| ROE | 0.47 | 0.35 | -0.89 | |
| Capex per share | -0.23 | -0.18 | -0.45 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 0.04 | 0.03 | 0.04 | 0.02 | |
| Net income per share | -1.3 | -0.96 | -0.76 | -0.7 | -1.13 | |
| Operating cash flow per share | -1.08 | -0.69 | -0.63 | -0.43 | -0.53 | |
| Free cash flow per share | -1.22 | -0.76 | -0.69 | -0.48 | -0.61 | |
| Cash per share | 7.44 | 4.85 | 3.76 | 3.27 | 2.06 | |
| Book value per share | 7.33 | 4.66 | 3.98 | 3.34 | 2.29 | |
| Tangible book value per share | 6.77 | 4.24 | 3.5 | 2.87 | 2.22 | |
| Share holders equity per share | 7.33 | 4.66 | 3.98 | 3.34 | 2.29 | |
| Interest debt per share | 1.07 | 0.81 | 0.49 | 2.4 | 1.89 | |
| Market cap | 3.11B | 1.35B | 686.45M | 297.99M | 127.28M | |
| Enterprise value | 2.61B | 931.76M | 344.3M | 200.02M | 99.81M | |
| P/E ratio | -7.7 | -3.43 | -2.2 | -1.03 | -0.27 | |
| Price to sales ratio | 527.88 | 330.18 | 225.88 | 65.43 | 52.66 | |
| POCF ratio | -36.97 | -19.11 | -10.59 | -6.66 | -2.32 | |
| PFCF ratio | -32.72 | -17.23 | -9.67 | -6.02 | -2.02 | |
| P/B Ratio | 5.46 | 2.83 | 1.68 | 0.87 | 0.54 | |
| PTB ratio | 5.46 | 2.83 | 1.68 | 0.87 | 0.54 | |
| EV to sales | 443.32 | 228.26 | 113.29 | 43.92 | 41.29 | |
| Enterprise value over EBITDA | -28.01 | -10.39 | -5.21 | -3.41 | -0.98 | |
| EV to operating cash flow | -31.05 | -13.21 | -5.31 | -4.47 | -1.82 | |
| EV to free cash flow | -27.48 | -11.91 | -4.85 | -4.04 | -1.58 | |
| Earnings yield | -0.03 | -0.07 | -0.11 | -0.24 | -0.92 | |
| Free cash flow yield | -0.03 | -0.06 | -0.1 | -0.17 | -0.5 | |
| Debt to equity | 0.14 | 0.17 | 0.11 | 0.69 | 0.79 | |
| Debt to assets | 0.11 | 0.13 | 0.08 | 0.39 | 0.4 | |
| Net debt to EBITDA | 5.34 | 4.64 | 5.18 | 1.67 | 0.27 | |
| Current ratio | 11.71 | 4.28 | 5.54 | 4 | 4.59 | |
| Interest coverage | -35.29 | -33.91 | -11.19 | -7.97 | -11.42 | |
| Income quality | 0.83 | 0.72 | 0.83 | 0.62 | 0.47 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.02 | 4.39 | 7.28 | 5.21 | 10.05 | |
| Research and developement to revenue | 8.52 | 9.57 | 9.9 | 6.31 | 12.9 | |
| Intangibles to total assets | 0.06 | 0.07 | 0.09 | 0.08 | 0.02 | |
| Capex to operating cash flow | 0.13 | 0.11 | 0.1 | 0.11 | 0.15 | |
| Capex to revenue | -1.86 | -1.89 | -2.03 | -1.05 | -3.44 | |
| Capex to depreciation | -2.22 | -1.33 | -1.11 | -0.87 | -1.76 | |
| Stock based compensation to revenue | 1.18 | 1.33 | 2.2 | 1.62 | 3.58 | |
| Graham number | 14.63 | 10.03 | 8.26 | 7.25 | 7.61 | |
| ROIC | -0.15 | -0.17 | -0.16 | -0.08 | -0.18 | |
| Return on tangible assets | -0.15 | -0.17 | -0.17 | -0.13 | -0.25 | |
| Graham Net | 5.53 | 3.43 | 2.7 | 0.66 | -0.14 | |
| Working capital | 554.38M | 395.91M | 333.8M | 265.15M | 187.45M | |
| Tangible asset value | 525.73M | 433.82M | 359.31M | 295.49M | 229.24M | |
| Net current asset value | 450.05M | 366.04M | 293.44M | 79.49M | 5.3M | |
| Invested capital | 0.14 | 0.17 | 0.11 | 0.69 | 0.79 | |
| Average receivables | 5.28M | 4.53M | 2.86M | 2.74M | 3.05M | |
| Average payables | 15.41M | 12.36M | 7.95M | 5.89M | 9.62M | |
| Average inventory | 5.82M | 6.08M | 6.12M | 6.02M | 6.05M | |
| Days sales outstanding | 98.52 | 57.88 | 91.36 | 47.41 | 137.63 | |
| Days payables outstanding | 58.71 | 54.86 | 50.88 | 46.04 | 119.08 | |
| Days of inventory on hand | 24.54 | 32.53 | 56.68 | 43.32 | 56.48 | |
| Receivables turnover | 0.91 | 1.56 | 0.99 | 1.9 | 0.65 | |
| Payables turnover | 1.53 | 1.64 | 1.77 | 1.95 | 0.76 | |
| Inventory turnover | 3.67 | 2.77 | 1.59 | 2.08 | 1.59 | |
| ROE | -0.18 | -0.21 | -0.19 | -0.21 | -0.49 | |
| Capex per share | -0.14 | -0.08 | -0.06 | -0.05 | -0.08 |
ZY Frequently Asked Questions
What is Zymergen Inc. stock symbol ?
Zymergen Inc. is a US stock , located in Emeryville of Ca and trading under the symbol ZY
What is Zymergen Inc. stock quote today ?
Zymergen Inc. stock price is $- today.
Is Zymergen Inc. stock public?
Yes, Zymergen Inc. is a publicly traded company.
Company Profile
- Volume Average 1.04M
- Employee 502
- CEO Mr. Joshua J. Hoffmann
- Headquarters EmeryVille,CA,US
- IPO Date 2021-04-22
-
Website
https://www.zymergen.com 
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
